PDFファイル - 医薬品医療機器総合機構
Contents
1. 2 8 28 GTP 200A C 4mL X10 GTP 210A C _ 10mL X10 1 Quick AJ Hemorrhagic diseases and thrombosis Philadelphia Lea and Febiger 1966 2 Poller L The prothrombin time WHO LAB 98 3 1998 3 Clinical Laboratory Standards Institute Collection transport and processing of blood specimens for testing plasma based coagulation assays Approved Guideline Fourth Edition CLSI document H21 A4 CLSI 940 West Valley Road Suite 1400 Wayne Pennsylvania 19087 1898 USA 2003 4 Tripodi A Chantarangku l V Clerici M et al Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant Results of a collaborative study involving nine commercial thromboplastins Br J Haematol 2001 115 672 8 5 Tobu M Iqgbal 0 Messmore HL et al Influence of different anticoagulant agents on fibrinopeptide A generation Clin Appl Th2. 3 4 N 1 P 2 3 B4216 G1 J7801 985 2 2 8 2SD gt 2 5SD
3. m 138 5 95 CA 7000 90 2 1NR 1 1 10 8 13 5 1 4 17 10 0 11 7 WW 10 8 13 5 17 0 26 0 3 5 CV 5 3 PT 0 140 5 n 57
4. 0 983 Y 0 985X 0 235 2 FNP Fresh Norma1 Plasma Poo1 1 1 2 1 2 8C 2 3 2 8 5 4 5
5. 6 7 15 30 8 9 10 11 3 1 HIV HBV HCV 1 000ppm 1 121 20 2
6. 37 C 5 2 1 B4216 G1 J7801 985 2 INR 3 4
7. 1 1 2 4 2 3 1009 4 2 PT PR 3 INR Internationa1 Normalized Ratio PR TSI INR PR I ISI International Sensitivity Index 1SI WHO C 37C 1 2 5 PR 409295004N 1
8. K HL VI X PT TH V ET A OR C PT 0 11mo1 VI V Xase ase V Xx PT PT 1
9. 1 2 3 4 2 8 2 8C 5 15 25C 24 37C 8 37 8 8 2 1 0 1mL 2 37 0 2mL
10. 1 70 2 2 8 4 3 4 0 11mo1 5 9 0 11mo1 1 1500xg 15 CLS1 H21 A4 4
11. SIEMENS HH 20600AMYO0289000 8 2008 9 2 2006 3 1 C THROMBOPLASTIN 1 2 3 4 PT 1935 A Quick 3 1 a RP RA I 3
12. romb Hemost 2003 9 273 92 6 Fenyvesi T Joerg I Harenberg J Argatroban and Melagatran on additional effect of oral 2002 48 1791 4 7 Tobu M Iqbal 0 Hoppensteadt D et al Anti Xa and anti lla drugs alter International Normalized Ratio measurements Potential problems in the monitoring of oral anticoagulants Clin Appl Thromb Hemost 2004 10 301 9 8 Hirsh J Dalen JE Anderson DR et al Oral anticoagulants Mechanism of action clinical effectiveness and optimal therapeutic range Chest 2001 119 8S 21S CS 1 3 2 651 2241 TEL 0120 418 034 1 5 1 651 0073 TEL 078 265 0500 Tnfluence of Lepirudin prothrombin time and anticoagulation Clin Chem IVD EXP LOT N CC cms Al Wy 409295004N 2008 Siemens Healthcare Diagnostics Products GmbH All rights reserved
Download Pdf Manuals
Related Search